ランキングに戻る

Sotera Health Company (SHC)

割高
HealthcareDiagnostics & ResearchUnited States

ファンダメンタル

58

株価

$18.36

時価総額

$5.28B

パート1 · 企業の価値

概要

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

貸借対照表と流動性

売上高

$1.22B

直近12か月(2026/6/30まで)

純利益

$163M

直近12か月(2026/6/30まで)

フリーキャッシュフロー

$149M

自己資本合計

$606M

負債合計

$2.66B

流動比率

2.80

利払い倍率

-

負債/EBITDA

3.93

一株当たり利益(EPS)

売上高と純利益

フリーキャッシュフロー

収益内訳

財務推移表

利益率の推移

負債の推移

負債の重さ

成長率グリッド

成長率 — 売上高

適正価値の推定

一般的なケース割高

適正価値

$13.10

現在株価

$18.36

安全マージン

-40.1%

適正価値レンジ

$8.51 - $17.68

使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。

推定方法

アナリストの目標株価:$22.72
ディスカウンテッド・キャッシュフロー(DCF):$6.62
利益倍率(P/E):$10.04
グレアムの成長公式:$9.12
収益力価値(EPV):$7.14
正当化されたP/B:$4.06
配当割引モデル(ゴードン):算出に必要なデータが不足しています
P/FFO(運用から生まれる資金):$9.69
中間サイクル利益:$21.47
売上高倍率:$16.57
アナリスト・コンセンサス:強い買い (12B / 3H / 0S)
直近の決算サプライズ:+7.62%

バリュエーション指標

P/E レシオ

31.79

ROE

12.9%

P/B レシオ

7.77

P/FCF

45.88

粗利益率

55.0%

ROIC

-

収益性レーダー

価値創造(経済的モート)

ROIC

-

WACC

10.7%

ROIC − WACC

-

ファンダメンタル分析基準

合格(13)

  • EPS shows upward trend
  • Gross Margin 55.0%
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 26.8%
  • Revenue Growth 5Y 7.3%
  • Analyst Consensus 80% Buy
  • Earnings Surprise avg 8.4%
  • Earnings Quality (OCF/NI) 1.79
  • Net Margin Trend 13.4% vs 2.1%
  • Piotroski F-Score 6/9

不合格(9)

  • Price CAGR -6.54%
  • P/FCF 45.88
  • P/B Ratio 7.77
  • Debt/Equity ratio
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Share Dilution 4.0%

データなし(5)

  • ROIC NaN%
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Interest Coverage
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-スコア

6/9

まちまちのシグナル:一部の領域に注意が必要

score
criteria

利益の質

1.79

高品質:利益はキャッシュに裏付けられている

株式希薄化

4.0%

新株を発行しており、所有権を希薄化している

機関投資家の保有

ガバナンス

経営陣

氏名役職年齢
Mr. Michael B. Petras Jr.Executive Chairman of the Board56
Mr. Jonathan M. LyonsSenior VP & CFO47
Mr. Michael P. RutzPresident of Sterigenics U.S., LLC54
Mr. Alton E. ShaderCEO & Director52
Mr. Robert G. HauzieChief Information Officer-
Ms. Erika OstrowskiSenior VP, General Counsel & Corporate Secretary-
Ms. Kristin A. GibbsChief Marketing Officer-
Mr. William O. Lehmann Jr., J.D., M.B.A.Senior Vice President of Strategy & Corporate Development59
Ms. Sally R. TurnerChief Human Resources Officer-
Ms. Danielle J. MentureSenior Vice President of Global Environmental, Health & Safety and Sustainability-

監査リスク

4

取締役会リスク

8

報酬リスク

5

株主権利リスク

7

パート2 · 株価と買い時

この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。

書類

  • 年次報告書(10-K)

    事業内容、財務実績、リスクをまとめた年次の概要。

    提出日: 2026-02-24

    書類を見る
  • 四半期報告書(10-Q)

    直近3か月間の業績に関する最新情報。

    提出日: 2026-08-06

    書類を見る
  • 臨時報告書(8-K)

    経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

    提出日: 2026-08-14

    書類を見る

via SEC EDGAR

業績推移

via SEC EDGAR

Latest News

Recent headlines for SHC, sourced from Markets Gazette.

  • 3/15/2026NEUTRAL
    Sotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals

    Sotera Health Company shares have seen an 18% increase over the past year, with recent activity indicating a significant stake trim by an insider amounting to $37 million. Sotera Health provides crucial sterilization and laboratory testing services to highly regulated industries globally, playing a vital role in maintaining essential supply chains. While the stock has performed well, the substantial insider sale could signal a divergence of opinion on future valuation or a need for liquidity, warranting investor attention.

  • 3/2/2026NEGATIVE
    Sotera Health Up 30% This Past Year, so Why Did One Fund Sell $4 Million in Shares?

    Sotera Health, a global provider of sterilization and laboratory solutions to the healthcare, pharmaceutical, and food industries, has seen an impressive 30% growth over the past year. Despite this robust performance, an unidentified fund divested $4 million worth of shares. This move raises questions among investors: why would an institutional entity sell such a significant stake in a rapidly growing company? It could signal strategic profit-taking, a portfolio rebalancing, or potentially a less optimistic view on the company's future prospects not yet apparent to the broader market. Investors should closely monitor upcoming developments and the rationale behind this significant divestment.

  • 2/24/2026NEUTRAL
    Insights into Sotera Health Q4 Earnings

    Investors are keenly awaiting insights into Sotera Health's fourth-quarter earnings, a pivotal event for assessing the company's performance and future outlook. Analyzing quarterly results is crucial for understanding financial health, revenue growth, and profitability, all of which directly influence market sentiment and investment decisions. While specific details are yet to be disclosed, market focus remains on how Sotera Health navigated operational challenges and opportunities during the period. Key data points, such as revenue, earnings per share (EPS), and future guidance, will be scrutinized to identify trends and potential catalysts for the stock price. Results meeting or exceeding expectations could bolster confidence, whereas a disappointment might trigger a negative reaction.

via Markets Gazette